Related Experiment Video
Updated: Feb 17, 2026
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs
Daniel N Wolfe1, Amanda G Zarrabian1, Gary L Disbrow1
1Health and Human Services (HHS)/Assistant Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA), Thomas P. O'Neill Federal Building (FOB8), 200 C Street, SW, Washington, DC 20024, United States.
Abstract:
The Ebola virus epidemic in West Africa proved to be the largest in the history of filovirus outbreaks, causing the World Health Organization to declare a public health emergency of international concern in August of 2014. In collaboration with domestic and international partners, the Biomedical Advanced Research and Development Authority (BARDA) initiated several vaccine development projects in support of the overall response efforts. The urgency associated with the epidemic triggered the clinical evaluation of lead vaccine candidates starting in late 2014. Here we will discuss development of the lead vaccine candidates for Ebola virus, specifically Zaire ebolavirus.
